Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
about
A Summary of the Biological Processes, Disease-Associated Changes, and Clinical Applications of DNA Methylation.Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection.Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum.New insights into colorectal cancer screening and early detection tests
P2860
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
@en
type
label
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
@en
prefLabel
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
@en
P2860
P1476
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
@en
P2093
Sohita Dhillon
Yvette N Lamb
P2860
P2888
P304
P356
10.1007/S40291-017-0259-Y
P577
2017-02-02T00:00:00Z
P6179
1083524432